Analystreport

BIOLINERX LTD/S (NASDAQ: BLRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.50 price target on the stock.

BioLineRx Ltd. - American Depositary Shares  (BLRX) 
Last biolinerx ltd. - american depositary shares earnings: 5/14 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.biolinerx.com